Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with … – DailyFinance

Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with
DailyFinance
As of May 17, 2013, the trial has completed enrollment and 110 patients have received 264 doses of ADXS-HPV (ADXS11-001). Final 12 month overall survival is 36% (39/110) with a (current) 18 month survival of 22% (16/73). This compares to 33% and 17%

and more »

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *